Symbols

KYNB

Kyntra Bio·NASDAQ

--(--)

KYNB fundamentals

KYNB Q4 2025 Earnings

Kyntra Bio (KYNB) released its earnings on Mar 16, 2026: revenue was 1.30M (YoY -58.55%), missed estimates; EPS was -3.51 (YoY -178.00%), beat estimates.

Revenue / YoY

1.30M

-58.55%

EPS / YoY

-3.51

-178.00%

Report date

Mar 16, 2026

KYNB Earnings Call Summary for Q4,2025

Financial Restructuring Success: 2025 net loss reduced 62% to $58.2M; cash runway extended to 2028 via $109.4M balance.
FG-3246 Milestone: Phase II interim data due H2 2026; 10+ month rPFS target in post-ARPI setting.
Roxadustat Catalyst: FDA Phase III feedback expected; $7M+ orphan exclusivity for MDS anemia.
Imaging Innovation: FG-3180 PET agent could unlock $5B+ CD46-targeted ADC market.

Earnings

EPS

Revenue

Revenue & Expenses

KYNB has released its 2025 Q4 earnings report, with revenue of 1.28M, reflecting a YoY change of -59.27%, and net profit of -14.22M, showing a YoY change of -179.08%. The Sankey diagram below clearly presents KYNB's revenue sources and cost distribution.

Key Indicators

Kyntra Bio (KYNB) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kyntra Bio (KYNB)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kyntra Bio (KYNB)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kyntra Bio (KYNB)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown